Digital Ally, Inc. (NASDAQ:DGLY)

Shares of Digital Ally, Inc. (NASDAQ:DGLY) are up 18% after the company won a court ruling which should send the issue to trial. The market reacted favorably to the decision by the Federal District Court of Kansas after it rejected the request of Axon Enterprise, Inc. (Axon) to maintain the stay of the patent lawsuit brought against it by Digital Ally.

Digital Ally, headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Its products are distributed globally. The company’s products include in-car and body cameras, cloud and local management software, and automatic recording technology. The products have been designed to work seamlessly together.

On November 8, 2017, the company’s Board of Directors decided to explore strategic alternatives. Avenues may include monetizing its patent portfolio and related patent infringement litigation against Axon, the sale of Digital Ally as a whole, or the sale of select properties or groups of properties or individual businesses. The result of the strategic review may also include the continued implementation of the company’s business plan. The Company has retained Roth Capital Partners LLC to assist in this process.

Digital Ally Accused of Patent Infringement

The litigation between Digital Ally, Inc. (NASDAQ:DGLY) and Axon involves two patents — the ‘452 Patent and U.S. Patent No. 8,781,292 (“the ‘292 Patent”). The ‘452 Patent generally covers the automatic activation and coordination of multiple recording devices in response to a triggering event such as a law enforcement officer activating the light bar on the vehicle. Within the Axon product family, the “Signal” component is responsible for this functionality. The ‘292 Patent is asserted against Axon’s Signal Performance Power Magazine (SPPM) – a battery pack that incorporates Signal and is designed to activate one or more body cameras when the safety of a conducted electrical weapon is deactivated.

On July 6, 2017, the U.S. Patent Office denied Axon’s petition for inter partes review of Digital’s ‘452 Patent. On August 3, 2017, the Patent Office denied Axon’s final petition for IPR of the ‘452 Patent. This was Axon’s final attempt to invalidate the ‘452 Patent before the Patent Office.

Last Friday, November 17, 2017, the Court rejected Axon’s request and lifted the stay of the litigation. In ruling on the motion regarding the stay, the Court found that the evidence submitted by Digital Ally, Inc. (NASDAQ:DGLY) “weigh heavily against continuing the stay of the ‘452 patent” and that “the Court denies Defendant’s [Axon’s] request to continue the stay of this case with respect to the ‘452 patent.” The Court has set a hearing for December 14, 2017, to discuss a schedule for moving the case forward to trial.

DGLY Stock Performance

Digital Ally, Inc. (NASDAQ:DGLY) has a market capitalization of $16.1 million and a float of just 5.73 million shares. This makes it a frequent subject of day-trading chat rooms and frequent jumps in trading volume.

Year-to-date, DGLY stock has lost over 44% but is up 4.5% for the past week. It has a consensus, one-year target price of $6 – a price which was established early in 2017 and is also its 52-week high. Since then, the stock has largely slid downwards to $1.70, its 52-week low which was hit earlier this month.

Three investment firms cover Digital Ally, Inc. (NASDAQ:DGLY). Two rate DGLY stock as a “strong Buy”, while one rates the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DGLY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Acasti Pharma Inc (NASDAQ:ACST)

Acasti Pharma Inc (NASDAQ:ACST) stock was up over 155%, to $3.25, before retreating in the first 45 minutes of trading to the $2.25 handle for a 75%+ gain over Friday’s close of $1.27. Volume has been massive – almost 1,900 times the daily average. The move comes after the biopharmaceutical company announced entering into a non-binding, licensing term sheet with a leading China-based pharmaceutical company.

Acasti Pharma Inc (NASDAQ:ACST), headquartered in Quebec, Canada, is a biopharmaceutical company that is developing the cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia. This condition affects an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia.

Acasti Deal

At this stage, the licensing deal is non-binding. Upon its execution, the proposed term sheet expects that Acasti would receive an upfront payment of $8 million, additionally there would be regulatory and commercial milestone payments in excess of $125 million, and tiered double-digit royalties on net sales.

The deal grants an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in China and other specified Asian countries. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant commercial opportunity for both Acasti Pharma Inc (NASDAQ:ACST) and CaPre.

Acasti’s press release specifies that the deal is not yet agreed to, and conditions and terms may change from those that have been released to the public.

ACST Stock Performance

Shares of Acasti Pharma Inc (NASDAQ:ACST) have been largely flat for the year, losing 5.2% prior to today’s price action. It has been trading in a range between $1.20 and $1.40 for most of 2016 and 2017, but briefly spiked to hit a 52-week high of $2.46.

In August, the company reported its Q1 2018 financial results. Its net loss was C(-$2.8) million or C(-$0.19) per share which was an improvement on its performance for the same period of the prior year when the loss was C(-$3.2) million or C(-$0.29) per share.

Acasti Pharma Inc (NASDAQ:ACST) has a low float figure of 8.1 million shares which makes it a favorite of momentum traders. ACST stock has a Relative Strength Index score of 90 which places it well into the metric’s range that most observers consider to be in “overbought” status.

ACST shares have a listed one-year target share price of $8.21.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Tantech Holdings Ltd (NASDAQ:TANH)

Tantech Holdings Ltd (NASDAQ:TANH) traded lower days after announcing the appointment of Dr. Yonghua Zhu who is to spearhead the development of the company’s electric vehicle business. Shares of the company fell 3.8% in Wednesday’s trading session, to end the day at $3.04 a share.

Electric Vehicles Ambitions

Mr. Zhu, as the Chief Scientist Officer, is to oversee the company’s automotive projects with focus on research and development of autonomous driving technology for electric vehicles. He joins the company with vast experience in wireless transmission technology research and development.

He is currently involved in the development of electric vans. Zhu has also teamed up with a Taiwan based company to develop battery management system for electric vehicles to be used for the Hong Kong market.

According to Tantech Holdings Ltd (NASDAQ:TANH) CEO, Zhengyu Wang, the appointment marks an important milestone in the company’s push to build up technical reserves for long-term development. However, it is not expected to have any financial impact on the company in the short term.

“The appointment is in line with the Company’s strategy of developing expertise in products and services used for the electric vehicle sector to build a supply chain covering China’s entire automotive industry,” said Mr. Wang.

Despite coming under pressure in Wednesday’s trading session, Tantech Holdings Ltd (NASDAQ:TANH) has been on an impressive run, ever since it announced its plans for electric vehicles. In October alone, the stock has gained more than 10% in market value. For the full year, the stock is up by more than 50% as it continues to trade in an uptrend.

Public Offering

Separately, Tantech Holdings Ltd (NASDAQ:TANH) has announced the closing of a previously announced securities purchase agreement with certain institutional investors. The company issued 1.9 million shares to the institutional investors at a price of $3.45 a share. The company also issued warrants for the purchase of up to 945,655 common shares at an exercise price of $4.25 a share.

Tantech holdings expect gross proceeds of about $6.5 million from the offering. Net proceeds from the offering are to be used for general and working capital purposes.

Tantech Holdings Ltd (NASDAQ:TANH) will hold its 2017 annual meeting of shareholders on December 18, 2017. Only shareholders on record as of November 1, 2017, will be entitled to vote at the meeting.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TANH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

SemiLEDs Corporation (NASDAQ:LEDS)

SemiLEDs Corporation (NASDAQ:LEDS) stock is up over 1700% after the memory chip manufacturer announced it would be releasing their Q4, 2017 financial results after the market close. LEDS stock was trading below yesterday’s close until the company made the announcement, then the stock shot up from $2.75 to over $7.50 just after 12:30PM EST. Volume is over 130 times the daily listed average.

SmeiLEDS Files Preliminary Results

However, prior to this morning’s announcement, SemiLEDs Corporation (NASDAQ:LEDS) filed an 8-K form with the SEC and provided preliminary results for the quarter ended August 31, 2017. Revenue for Q4 2017 was $2.6 million, a 22% increase compared to $2.1 million for Q3 2017. GAAP net loss attributable to SemiLEDs stockholders for the fourth quarter of fiscal 2017 was (-$0.7) million, compared to a loss of (-$1.6) million for Q3 2017, or a net loss of (-$0.19) per diluted share, compared to a net loss of (-$0.45) per diluted share for Q3 2017. Cash and cash equivalents was $3.6 million as of August 31, 2017, compared to $3.1 million at the end of the third quarter of fiscal 2017. The net cash inflows in operating activities were $0.5 million in the fourth quarter of fiscal 2017, compared with net cash outflows $0.9 million in the third quarter of fiscal 2017.

SemiLEDs Corporation (NASDAQ:LEDS), based in Chunan, Taiwan, develops and manufactures LED chips and LED components primarily for general lighting applications, including street lights and commercial, industrial and residential lighting, along with specialty industrial applications such as ultraviolet (UV) curing, medical/cosmetic, counterfeit detection, horticulture, architectural lighting and entertainment lighting. SemiLEDs sells blue, white, green and UV LED chips.

LEDS Stock Performance

Sales have been declining for SemiLEDs Corporation (NASDAQ:LEDS). In 2012, the company reported sales of $29.3 million. For 2016, the company’s sales were only $10.1 million. However, with one exception, EPS losses have been contracting annually. In 2012 the EPS loss was (-$18.04), and that number shrank to (-$7.25) by 2016.

Over the past quarter, LEDS stock has performed well – gaining over 30%. Unfortunately, the shares are down over 20% for the year.

It should also be noted that, as of the market open, LEDS stock had a sizeable short seller position of over 20% of the stock’s float.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LEDS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN)

Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) stock is up over 30%, but have dropped from prices that hit multi-year highs. The daily average volume for OSN stock is just over 10,000 shares. However today, by 1:15 PM EST, over 1.8 million shares have exchanged hands. The substantial price and volume increase is curious to market observers as no news has been announced by the company or financial press that could account for the dramatic increases.

OSN Stock Performance

In late September, OSN stock hit its 52-week low of $1.50. Today the stock has been as high as $3.61, but sellers stepped in and the stock is now trading around the $2.75 level. Out of the past 12 trading sessions, OSN stock has ended the day higher eleven times.

Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) per share earnings increased annually from 2012 $0.36, to 2015, $0.89. But in 2016 the company reported a lower figure of $0.73. Sales have been largely flat. In 2012 the company posted sales of $122.4 million and by 2016 that number was just $117 million.

OSN stock has gained just 3% year-to-date, but returned over 23% over the past month.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

LightPath Technologies, Inc. (NASDAQ:LPTH)

Last Friday, LightPath Technologies, Inc. (NASDAQ:LPTH) shares dropped over 22%, and closed at $2.91, after the company released Q1 2018 earnings after the market closed on Thursday. The market punished shares of the electrical equipment manufacturer after earnings beat results from the same period last year, but were below analyst estimates.

Lightpath Earnings Report

LightPath Technologies, Inc. (NASDAQ:LPTH) reported Q1 2018 EPS at $0.01, while analysts were expecting $0.03. Revenues came in at $7.6 million but analysts were looking for a figure of $8.4 million. LPTH stock gapped down on the news and opened at $3.40 after closing on Thursday at $3.74. Shares continued to dive until the last hour of trading and hit a daily. Shares settled the day at $2.91.

The earnings report showed improvements on many fronts, but the improvements were not as aggressive as the market was expecting. Q1 2018 revenue increased 51% to approximately $7.6 million, as compared to approximately $5.0 million for Q1 2017. Adjusted net income, which excludes the non-cash income or expense related to the change in fair value of their stock warrant liabilities, were approximately $169,000, versus approximately $97,000 for the same period last year. Adjusted EBITDA, which excludes the non-cash income or expense related to the change in fair value of our warrant liability, was approximately $1.2 million, an increase of 99%, as compared to $619,000 for Q1 2017.

LPTH Stock Performance

LightPath Technologies, Inc. (NASDAQ:LPTH) has more than doubled sales since 2014 when the company posted a figure of $11.8 million. That number was $28.4 million for 2017. Earnings have also shown improvement. In 2015, LPTH EPS was (-$0.05), but that was followed by two years of positive EPS. For 2017 the EPS profit was $0.39.

Investors rewarded the company over the past year by buying the shares and sending the stock up over 70%. For the year, LPTH shares are up nearly 90%. The analysts’ consensus, one-year price target was, before Friday, $3.05.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LPTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

TOP SHIPS Inc (NASDAQ:TOPS)

TOP SHIPS Inc (NASDAQ:TOPS) stock dropped over 17% and ended the trading day at $0.72 on volume that was over three times normal. TOPS stock has struggled to remain over the $1 per share level which serves not only as a psychological level, but is also a key level to maintain NASDAQ compliance.

The Board of Directors for Greek-based TOP SHIPS Inc (NASDAQ:TOPS) has approved, and enacted, several reverse splits in the last few years. In 2014, there was a 1:7 reverse split, then in 2016 there was a 1:10 reverse stock split. In 2017 there have been four. In May, the reverse split ratio was 1:20, in June it was 1:15, in August the ratio was 1:30, and last month the company ordered a reverse split using a ratio of 1:2.

Taking the reverse splits into account, TOPS stock traded at an astounding $250,000 per share in 2009. The extreme destruction of TOPS shareholder equity is the basis for a number of class-action lawsuits and SEC investigations.

TOPS Lawsuits

The lawsuits allege that TOP SHIPS Inc (NASDAQ:TOPS) CEO Evangelos J. Pistiolis caused the company to engage in a series of manipulative share issuance and sales transactions with Kalani Investments Limited (“Kalani”) through which Top Ships would sell its common shares and securities convertible into common shares to Kalani at a significant discount to market price and file registration statements so that Kalani could resell these shares into the market. When Kalani’s sales of TOP SHIPS Inc (NASDAQ:TOPS) stock caused its share price to decline, the company would reverse split the stock thereby raising its stock price.

The lawsuits continue to allege that the TOP SHIPS Inc (NASDAQ:TOPS) would continue to manipulate the stock price and lending arrangements by selling additional securities to Kalani. Then the same lending and trading pattern would follow. Allegations state that the company failed to disclose the true purpose of the transactions and related stock issuances and reverses – to finance related-party transactions and acquisitions that primarily benefited Mr. Pistiolis and company insiders.

What is a matter of record is that by August 2017, TOP SHIPS Inc (NASDAQ:TOPS), through Kalani, issued and sold into the market tens of millions of shares of TOPS common stock, vastly diluting shareholder equity. The value of TOPS stock has fallen by more than 99% in the past year.

TOP SHIPS New Debt

On Friday, TOP SHIPS Inc (NASDAQ:TOPS) announced that it will enter into a note purchase agreement for the issuance of a revolving promissory note with Crede Capital Group LLC, a Delaware limited liability company, in the amount of $12.5 million with a single revolving option for an additional $5.0 million note.

According to the press release, the two notes will have a 2-year term and will bear interest at 2% per annum for the first 90 days, 10% per annum for the next 90 days, and 15% per annum for the remaining duration of the term. The notes will be pre-payable at the election of the company at any time, will not be convertible into equity, and will begin to amortize upon their six-month anniversary. Proceeds will be used to expand the company’s fleet and for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TOPS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CPS Technologies Corporation (NASDAQ:CPSH)

Yesterday, CPS Technologies Corporation (NASDAQ:CPSH) announced their Q3 2017 earnings results and today the market responded by sending CPSH shares higher by 2.7% in early trading. Over the past six months, shares of the advanced materials manufacturer have traded between $1.10 and $1.35. Today’s morning trading saw shares open $0.08 higher than yesterday’s close and run up to the inter-day high of $1.30 before sellers stepped in and sent the stock back down to $1.15. Volume has been heavy – over 20 times the posted daily average.

CPS Technologies Business

Norton, MA-based CPS Technologies Corporation (NASDAQ:CPSH) develops and manufactures metal-matrix composite components used to improve the reliability and performance of certain electrical systems. CPS products are used in motor controllers for hybrid and electric vehicles, high-speed trains, subway cars and wind turbines. They are also used as heat-spreaders in internet switches, routers, and high-performance microprocessors. CPS Technologies Corporation (NASDAQ:CPSH) also develops and produces metal-matrix composites for the defense, aerospace, and oil & gas sectors.

CPS Technologies Q3 Earnings

CPS Technologies Corporation (NASDAQ:CPSH) announced revenues of $4.2 million and net income of $13 thousand for Q3 2017. This compares with revenues of $3.3 million and a net loss of $139 thousand for the quarter ended October 1, 2016.

Revenues for the nine months ended September 30, 2017 were $10.8 million compared with revenues of $12.5 million for the corresponding period a year ago- a 14% drop. The net loss for the nine-month period in 2017 totaled $925,000 compared with a $200,000 net loss for the first nine months of 2016.

Grant Bennett, CEO, said, “A year ago we reported that we expected the weakness in demand would persist for a few more quarters. This belief turned out to be accurate as it was not until the second quarter this year that we achieved a sequential increase in quarterly revenues. The upward trend continued this quarter which is 48% higher than our low point of Q1, 2017. As a result of the increase in revenues, we were able to generate above breakeven results for the first time in over a year.”

CPSH Stock Performance

Earnings have been decreasing each year since 2014 when the company posted a per share profit of $0.08. Last year, 2016, the company posted a per share loss of (-$0.03). That downtrend accompanied lower annual sales figures. Their best year was 2014 when they reported $23.1 million in sales. That number has declined each year since, and for 2016 sales were listed at $15.4 million.

CPSH shares are down almost 25% for the year and over 40% year-to-date. The current trading price is barely above the 52-week low of $1.02 and almost half the 52-week high of $2.20.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CPSH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Skyline Medical Inc (NASDAQ:SKLN)

Skyline Medical Inc (NASDAQ:SKLN) shares rose over 11% on the back of news that the fluid management systems firm announced a strategic collaboration to use their proprietary Helomics D-CHIP™ platform to develop new approaches for personalized cancer diagnosis and care. This collaboration is seen as part of Skyline’s attempt to diversify its revenue channels. SKLN shares ended Tuesday at $1.88 then gapped up to open at $2.26 before hitting their inter-day high of $2.50. SKLN stock closed at $2.09.

The Collaboration

Skyline Medical Inc (NASDAQ:SKLN) developed and produces a fully automated, patented, FDA-cleared waste fluid disposal system that claims to eliminate staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment.

Helomics has amassed large quantities of data on patients with cancer as part of its ChemoFx® precision cancer diagnostic. This “big-data” repository contains the drug response profiles of over 149,000 patient tumors and their molecular, genomic, biochemical and histopathology data coupled to de-identified patient demographics.

Dr. Carl Schwartz, Skyline Medical CEO, stated “Skyline Medical is building a more diversified business, and the Helomics collaboration is one more step along our path, helping patients, oncologists and pathologists to do a patient personalized medicine’s approach using AI and big data. We are very excited about this opportunity for Skyline and its shareholders.”

SKLN Stock Performance

SKLN shares have been trading between $1.50 and $2.00 for most of 2017. Year-to-date they are down almost 33% but are up over 26% over the past month. Their 52-week low is $1.20 and their 52-week high is $6.05.

The current uptrend has been reflected in their Relative Strength Index (RSI) score of 80. Most traders believe that a score above 70 indicates a stock is entering an “Overbought” condition.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SKLN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Oncobiologics Inc. (NASDAQ:ONS)

Oncobiologics Inc. (NASDAQ:ONS) fell 5.94% after announcing the closure of a previously announced strategic partnership with GMS Tenshi holdings. The partnership provides the clinical stage biopharmaceutical company with the financial muscle needed to accelerate the development and commercialization of biosimilar candidates.

Purchase & Exchange Agreement

Oncobiologics Inc. (NASDAQ:ONS) is down by more than 50% for the year, having underperformed the overall industry for the better part of the year. The stock is currently trading in a downtrend and close to its 52-week low of $0.90 a share.

Pursuant to a Purchase and Exchange Agreement signed in September, GMS Tenshi is to receive Series A Convertible Preferred stock in exchange for $25 million. The investor has also been offered the option of acquiring warrants, for the purchase of an additional 16.8 million shares, with an aggregate exercise price of $15 million.

“This investment will also significantly enhance our commercialization abilities in emerging markets, along with our partnering and licensing capabilities. Our new collaborator shares in our vision is to accelerate the commercialization of the BioSymphony™ Platform and our pipeline, in the hopes of bringing affordable biologic drugs to patients around the world,” said CEO Pankaj Mohan.

Oncobiologics board has elected Faisal G. Sukhtian and Joe Thomas to the board of directors to fill vacancies left by Robin Smith Hoke and Donald J. Griffith. The two will represent GMS Tenshi under the Investors Rights Agreement.

Development-License Agreement

The two companies have also entered into a joint development and License Agreement. The agreement provides GMS Tenshi with rights to Oncobiologics Inc. (NASDAQ:ONS) two lead biosimilar assets ONS-1045 and ONS-3010, in emerging markets of China, India, and Mexico.

Oncobiologics Inc. (NASDAQ:ONS) plans to use net proceeds from the private placement for Phase 3 trials of its lead biosimilar candidate ONS-3010. The company has already completed Phase 1 clinical trials and is now preparing to enter Phase 3 trials next year. The candidate drug is being developed as HUMIRA biosimilar.

“Our objective is to help Oncobiologics prepare ONS-3010 so that it can be launched alongside other first-wave HUMIRA® Biosimilars with potentially improved tolerability compared to the originator product as reported in the successful Phase 1 trial,” GMS Tenshi In a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Posts navigation

StockNewsUnion is a news gathering organization led by a team of unbiased, investment professionals dedicated to following the market’s biggest headline stocks on a daily basis. Our goal is to provide unmatched news and insight on newsworthy and momentum stocks to investors and traders worldwide.

Special attention is given to Nasdaq and listed US stocks trading under ten dollars that tend to have the largest street following.

We focus on identifying these companies and uncovering their stories before the rest of the market to ensure that you receive the full story – every single day.